The authors evaluated cardiac and hepatic iron deposition by MRI-based quantitation in hemodialysis patients who received intravenous iron supplements. They showed elevated hepatic iron deposition which was poor correlation with conventional haematic iron markers. This study showed interesting issues regarding iron overload in hemodialysis patients.
INTRODUCTION
The growing number of patients with diabetes mellitus and hypertension has been accompanied by an increased incidence of chronic kidney disease (CKD), 1 including end-stage kidney disease (ESKD). The 2015 ANZDATA report identified 12 091 ESKD patientstreatedwithperitonealdialysisorhaemodialysis(HD)inAustralia. 2 CKD is an inflammatory condition associated with high levels of circulating interleukin-6. This stimulates hepcidin production disrupting enteric iron absorption and tissue iron release. [3] [4] [5] This causes both absolute and functional iron deficiency and is one of the principle causes of anaemia in this population. Because anaemia is associated with increased mortality and morbidity, [6] [7] [8] HD patients are routinely prescribed erythropoetic stimulating agents (ESA) and parenteral iron to increase haemoglobin levels. 9, 10 TheKidneyHealthAustralia-CaringforAustralianswith
Renal Impairment guidelines on the use of iron in CKD patients recommend adjustments on iron dosage based on serum ferritin and transferrin saturation (TSAT) values. 10 This approach is inherentlyinaccurate,astheseparametersareinfluencedbythesystemic inflammation associated with CKD. 11, 12 The uncertainty is reflected in the varied recommendations of national-guidelines worldwide. Japanese recommendations in particular are more conservative than their Australian counterparts. 13, 14 Excess reabsorption or administration of iron leads to toxic accumulation, as there is no physiological mechanism for excretion. Surplus iron accumulates within metabolically active tissues, where it is transiently stored as ferritin. If the cell's storage capability is overwhelmed, free ferric ions may accumulate in the cytosol causing oxidative stress and eventually cell dysfunction or death. 15 Innovative magnetic resonance imaging (MRI) techniques such as FerriScan and T2*/R2* cardiac MRI provide a wellvalidated, non-invasive means to measure hepatic and cardiac iron deposition that is independent of systemic inflammatory states. 16, 17 Using R2* Ferriscan to measure liver iron concentrations (LIC), Ferrari et al. demonstrated elevated LIC in some HD patients receiving standard iron dosages, 12 and these findings were confirmed by Rostoker et al. 18 Although ESKD is associated with dysfunction of many organs, the liver is rarely a cause of significant morbidity in this cohort. The leading cause of death in HD patients is sudden cardiac death (SCD). 19 In these patients, coronary artery disease and heart failure are often not the underlying cause of SCD and other factors such as electrolyte shift or vascular calcification are presumed to play a greater role in SCD. 19 An alternative explanation for the high incidence of SCD in HD patients could be cardiac iron overload. Whether the observed increased LIC in dialysis patients 12 is accompanied by evidence of increased cardiac iron deposition has not been extensively investigated. Only one recent study reported on a lack of evidence for cardiac iron overload despite moderate liver iron overload both measured as T2* MRI in long-term HD patients. 20 However, there is poor agreement between T2*-LIC with R2-LIC (Ferriscan), 21 the latter being the method used in previous studies that assessed liver iron overload in CKD patient. 12, 18 Therefore, this pilot study was designed to evaluate the relationship of intravenous iron supplementation to hepatic measured by R2-Ferriscan and cardiac iron deposition measured by cardiac T2* in chronic HD patients.
METHODS
The study included patients on chronic maintenance HD that satisfied the following inclusion criteria: (i) maintenance HD for at least 12 months; (ii) standard parenteral iron therapy for at least 12 months; (iii) full history of all parenteral iron infusions and blood transfusions since commencing HD; (iv) no contraindications to MR imaging; (v) alcohol consumption of less than two standard drinks per day; and (vi) absence of liver disease, active malignancy, pregnancy or other confounding illnesses. Exclusion criteria were (i) absolute or functional iron deficiency (ferritin < 100 μg/L and/or TSAT 0< 20%), (ii) anaemia requiring transfusion, (iii) vitamin B12 or folate deficiency, (iv) parathyroid hormone level > 100 pmol/L, (v) urea reduction ratio < 65%, (vi) presence of systemic haematological disease (including antibody-mediated pure red cell aplasia) or known haemoglobinopathy, and (vii) major surgery, infection, acute myocardial infarction or malignancy within the last 3 months. The study was approved by the institutional Human Research Ethics Committee, and all patients gave their written informed consent to participate in the study. All subjects received iron polymaltose as a parenteral ironreplacement agent according to Kidney Health Australia -Caring for Australians with Renal Impairment guidelines. The ESA was Epoetin alfa in nine patients and Darbopoetin alfa in one; in the latter, the darbopoetin dose was converted to an erythropoietin-equivalent value using the recommended conversion factor of 200:1. Data on cumulative iron and ESA dose were obtained from review of dialysis unit and hospital medical records.
Biochemical and haematological parameters were collected as standard of care in the management of HD subjects, with the only non-standard of care intervention being the performance of MR for measurement of liver and cardiac iron concentrations. All scans and blood tests were acquired at least 14 days after the most recent iron infusion to avoid confounding results.
Liver R2* and cardiac T2* MRI Magnetic resonance imaging using a 1.5 T Siemens Magnetom Vision Plus machine and standardized T2*/R2* relaxometry techniques was performed to assess the extent of hepatic and cardiac iron deposition. 22 The LIC was measured by R2-Ferriscan as previously described by our group. 12, 16 Contiguous ferritin and TSAT levels were obtained to enable correlation between blood-based measures of body iron content and MR techniques. The reference range for LIC was 3-33 mmol/kg dry weight.
17
A LIC > 130 mmol/kg has been associated with liver injury and a LIC > 270 mmol/L has been associated with cardiac toxicity. 23 The cardiac T2* reference range was adapted from the work of Wood et al. 24 Cardiac T2* greater than 20 ms is not associated with apparent cardiac iron deposition. T2* readings of 10-20 ms are consistent with some cardiac iron deposition but little immediate risk of iron-induced cardiac decompensation. Values less than 10 ms represent significantly increased risk of iron-induced cardiac decompensation.
Statistical analysis
Statistical analysis was performed with STATA 13.1 (StataCorp. 2013, STATA statistical software, College Station, TX, USA: StataCorp LP) using standard parametric and nonparametric methods. Correlation coefficients were assessed using Pearson's method. All P-values are two-sided, and a P-value ≤ 0.05 was considered to be statistically significant.
RESULTS

Baseline data
Ten patients (three males and seven females) participated in this study. , and all patients were within the reference range. There was no correlation between LIC and cardiac T2* iron concentration (R 2 0.27, P = 0.12) (Fig. 1) .
Correlations between MRI and other key variables
There was a significant correlation between LIC and serum ferritin levels (R 2 0.63, P < 0.01). However, there was no significant correlation between LIC and either TSAT (R 2 0.004), cumulative iron dose (R 2 0.03) or time on dialysis (R 2 0.09).
There was no correlation between T2* and TSAT, serum ferritin, cumulative iron dose and number of days on dialysis.
DISCUSSION
Our study extends the observations of previous investigators 12, 18 by demonstrating that the majority (80%) of longterm HD patients receiving iron therapy exhibit significantly elevated LICs but with no increase in cardiac iron concentration. In fact, cardiac T2* results for all 10 study patients fell within normal limits, excluding cardiac iron overload in our cohort. This is consistent with the findings of Ghoti et al., 20 who performed MR examination of both liver and heart using MRI T2* studies in 21 HD patients in Israel. The lack of statistical significance is likely to be explained by the small sample size in the current study thus lacking the power to demonstrate the relationship of iron accumulation between two known target organs of iron overload. 15 Furthermore, only 20% of patients exceeded the LIC threshold for iron chelation in other settings, 23 compared with 60% in our previous study. 12 In the latter, the cumulative Fe dose was the strongest determinant of LIC, and on average, it was 25% higher in the previous cohort. 12 It is therefore possible that ESKD patients with evidence of more pronounced liver iron overload may demonstrate increased cardiac iron deposition. Thus, a high index of suspicion should be maintained for measurement of LIC using non-invasive MR-based methods in patients receiving large dosages of parenteral iron/ESA over a protracted period and who exhibit persistent hyperferritinaemia as this is the only method that is accurate for diagnosis of tissue iron overload in this setting. The clinical relevance of the LIC above the threshold for iron chelation 23 in dialysis patients is uncertain, as none had apparent hepatic decompensation on the basis of blood tests or physical examination. None of them had severely elevated LICs > 130 mmol/kg, a level associated with increased risks of liver injury and fibrosis in haemochromatosis. 25 Severely elevated LIC is used to identify subjects at risk of iron-induced cardiomyopathy in thalassaemia major and other transfusion dependent disorders. 24 No study patient approached this LIC threshold, and this may reflect the much lower levels of iron loading incurred during iron and ESA treatment of HD subjects. The estimated average cumulative iron dose of a transfusion-dependent thalassaemia major patient is 0.4 mg/kg per day, 26, 27 whereas our study patients received a mean 0.055 mg/kg per day. Post-mortem studies of HD patients in the 1970s-1980s demonstrated cardiac siderosis. 7, 28, 29 However, these took place at a time when anaemia was routinely treated with blood transfusions, ironreplacement regimes were less conservative and ESA were not routinely used. It is likely that such patients also received substantially larger cumulative iron dosages than would be typical today, thus accounting for the discrepancy. As ESA can induce production of erythroferrone, a known inhibitor of hepcidin production, 30 it is also possible that it may promote unloading of iron stored in various tissue repositories, including the liver and myocardium, potentially reducing the severity of iron loading. Results are median and 95% confidence interval (CI). BMI, body mass index; ESA, erythropoetic stimulating agents; LIC, liver iron concentration; TSAT, transferrin saturation. Fig. 1 Correlation between iron concentration in the liver, measured by R2*-Ferriscan and heart, measured by cardiac T2* MRI.
The poor correlation between LIC and TSAT levels in HD patients confirms previous observations by multiple groups. 12, 23, 31 It has been attributed to highly variable serum iron levels and TSAT in the context of intercurrent inflammation together with the effects of intermittent iron dosing and normal diurnal variation. Interestingly, we identified a moderate correlation with serum ferritin (R 2 0.63, P < 0.01) but not with either dialysis time or cumulative iron dose. Whilst at variance with an earlier observation by our group, 12 it demonstrates that ferritin levels may also be unreliable in the population of HD subjects as a guide of iron status. A possible explanation resides in differences between the two study cohorts as patients in this study received smaller cumulative iron dosages, had lower ferritin levels, a shorter HD duration and higher mean CRP. We conclude that adherence to current guidelines for ESA/parenteral iron replacement can result in LIC's above the upper limits of the reference range. However, cardiac siderosis does not accompany this increase in liver iron concentration. Therefore, these data suggest that current dosing of iron in haemodialysis is safe from a cardiac perspective with no sign of cardiac iron excess. Serum iron markers are poor predictors of either liver or cardiac iron deposition in HD subjects.
